Trial Search Results

Phase 2 Trial to Evaluate Safety and Efficacy of AU-011 Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection to treat primary indeterminate lesions and small choroidal melanoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Aura Biosciences

Stanford Investigator(s):


  • Drug: AU-011
  • Device: Suprachoroidal Microinjector
  • Device: PDT Laser


Phase 2


Inclusion Criteria:

   - Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)

   - Have no evidence of metastatic disease confirmed by imaging

   - Be treatment na├»ve for IL/CM

Exclusion Criteria:

   - Have known contraindications or sensitivities to the study drug or laser

   - Active ocular disease

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mariana Nunez